Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.65 |
| ▸ | AKT1 | P31749 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.63 |
| ▸ | JAK2 | O60674 | 11/20 | 0.61 |
| ▸ | JAK1 | P23458 | 5/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | AKT2 | P31751 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24804219 | 0.93 | LCK (0.67) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL30008783 | 0.86 | JAK2 (0.64) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL10074310 | 0.84 | DOT1L (0.86) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL15170325 | 0.84 | DOT1L (0.86) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL24805927 | 0.83 | AKT2 (0.67) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL30009536 | 0.83 | JAK2 (0.56) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL3951434 | 0.81 | JAK3 (0.65) | JAK3AKT1DOT1LJAK2JAK1 | |
| SCHEMBL12612717 | 0.80 | DOT1L (0.56) | JAK3AKT1DOT1LJAK2JAK1 | |
| SCHEMBL2019902 | 0.80 | JAK3 (0.62) | JAK3DOT1LJAK2JAK1LCK | |
| SCHEMBL12612895 | 0.80 | AKT1 (0.52) | JAK3AKT1DOT1LJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885AKT1 1203/4885DOT1L 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.